Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Experimental and molecular pathology (Print)

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.yexmp.2015.09.006PMID 26403329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

  2015cited by this paper
• Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

  2015cited by this paper
• BRAF inhibitors: From the laboratory to clinical trials.

  2014cited by this paper
• BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.

  2014cited by this paper
• Clinicopathological relevance of BRAF mutations in human cancer

  2013cited by this paper
• B-Raf mutation: a key player in molecular biology of cancer.

  2013cited by this paper
• Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation

  2013cited by this paper
• Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

  2013cited by this paper
• The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

  2012cited by this paper
• Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.

  2011cited by this paper
• The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation.

  2011cited by this paper
• Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

  2008cited by this paper
• Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

  2008cited by this paper
• Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• Akt1 in Endothelial Cell and Angiogenesis

  2006cited by this paper
• BRAF mutation in thyroid cancer.

  2005cited by this paper
• Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants

  2005cited by this paper
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

  2003cited by this paper
• Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention

  2003cited by this paper
• BRAF mutation in papillary thyroid carcinoma.

  2003cited by this paper
• Role of Akt Signaling in Vascular Homeostasis and Angiogenesis

  2002cited by this paper
• Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

  2000cited by this paper
• Anaplastic carcinoma of the thyroid.

  1999cited by this paper

• Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas.

  2024cites this paper
• From Bench to Bedside: What Do We Know about Imidazothiazole Derivatives So Far?

  2023cites this paper
• Antineoplastic Nature of WWOX in Glioblastoma Is Mainly a Consequence of Reduced Cell Viability and Invasion

  2023cites this paper
• Papillary Thyroid Carcinoma: Current Position in Epidemiology, Genomics, and Classification.

  2022cites this paper
• BRAF Mutations in Papillary Thyroid Carcinoma: A Genomic Approach Using Probe-Based DNA Capture for Next-Generation Sequencing.

  2022cites this paper
• Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics

  2021cites this paper
• Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma

  2020cites this paper
• Thyroid squamous cell carcinoma: a unique type of cancer in World Health Organization classification.

  2020cites this paper
• Potent Anti-Ovarian Cancer with Inhibitor Activities on Both Topoisomerase II and V600EBRAF of Synthesized Substituted Estrone Candidates

  2019cites this paper
• Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.

  2019cites this paper
• The Association Among Quantitative Contrast-Enhanced Ultrasonography Features, Thyroid Imaging Reporting and Data System and BRAF V600E Mutation Status in Patients With Papillary Thyroid Microcarcinoma.

  2019cites this paper
• IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.

  2018cites this paper
• Cribriform-morular variant of papillary thyroid carcinoma: a distinctive type of thyroid cancer.

  2017cites this paper
• Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

  2017cites this paper
• Novel FAM134B mutations and their clinicopathological significance in colorectal cancer

  2017cites this paper
• Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas

  2016cites this paper
• The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.

  2016cites this paper
• The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.

  2016cites this paper